



Limacorporate S.P.A.
% Lacey Harbour
Regulatory Manager
Lima USA Inc.
2001 NE Green
Arlington, Texas 76006

July 8, 2020

Re: K200656

Trade/Device Name: Delta Multihole TT Pro Acetabular System

Regulation Number: 21 CFR 888.3358

Regulation Name: Hip Joint Metal/Polymer/Metal Semi-Constrained Porous-Coated Uncemented
Prosthesis

Regulatory Class: Class II

Product Code: LPH, MBL

Dated: February 21, 2020

Received: March 12, 2020

Dear Lacey Harbour:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

FOR Vesa Vuniqi, MS
Assistant Director
DHT6A: Division of Joint Arthroplasty Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K200656

Device Name
Delta Multihole TT Pro Acetabular System

Indications for Use (Describe)

The Delta Acetabular System is indicated for use in total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients with the following conditions:

- Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis and hip dysplasia;
- Rheumatoid arthritis;
- Post-traumatic arthritis,
- Correction of functional deformity;
- Fractures, dislocation of the hip and unsuccessful cup arthroplasty;
- Revisions in cases of good remaining bone stock;
- Revision of previously failed total hip arthroplasty (Delta Multihole TT Pro only).

The Delta Acetabular System is intended for cementless use.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

Date: April 28, 2020

Manufacturer:
Limacorporate S.p.A.
Via Nazionale, 52
33038 – Villanova di San Daniele
Udine - Italy

U.S. Contact Person:
Lacey Harbour, MB(ASCP)^{CM}
US Regulatory Manager
Lacey.harbour@limacorporate.com
Limacorporate S.p.A.
2001 NE Green Oaks Blvd. Ste.100
Arlington, Texas 76006
USA
www.limacorporate.com
Office Phone: 817.385.0777 ext.200
Cell Phone: 432.638.6615
FAX: 817.385.0377

Product	Product Code	Regulation and Classification Name
Delta Multihole TT Pro Pro Acetabular System	LPH, MBL	Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis per 21 CFR 888.3358

Common name:
Acetabular Cup System

Description:
The Delta Multihole TT Pro Acetabular System consists of a Delta Multihole TT Pro cup, an acetabular liner and a modular femoral head. Bone screws can also be used to provide additional stability of the cup.

The Delta Multihole TT Pro cup is manufactured from titanium alloy; the Delta Multihole TT Pro liners are manufactured from cross-linked UHMWPE with Vitamin E and the femoral heads made of BioloX Delta ceramic or Cobalt Chrome Molybdenum alloy.

The design of shell is similar to the previously cleared sizes of Delta Multihole TT Pro Acetabular System (K191622) and the G7 Acetabular System (Biomet, Inc., K140669) devices. The acetabular liners, the BioloX Delta heads, the CoCrMo heads and the bone screws are the same as those cleared in K182099. The Multihole TT Pro cup has a hemispherical design and provides holes in cranial and caudal aspects of the cup to provide additional cup stability by means of fixation screws. The Multihole TT Pro cup is coupled with a Delta TT Pro acetabular liner that is available in neutral, protruded and high wall versions.

Intended Use/Indications:

The Delta Acetabular System is indicated for use in total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients with the following conditions:

- Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis and hip dysplasia;
- Rheumatoid arthritis;
- Post-traumatic arthritis,
- Correction of functional deformity;
- Fractures, dislocation of the hip and unsuccessful cup arthroplasty;
- Revisions in cases of good remaining bone stock;
- Revision of previously failed total hip arthroplasty (Delta Multihole TT Pro only).

The Delta Acetabular System is intended for cementless use.

Predicate Devices:

The LimaCorporate Delta Multihole TT Pro Acetabular System is similar to the following cleared devices in regard to design features, indications, and materials:

- Delta Multihole TT Pro Acetabular System (LimaCorporate, K191622), primary predicate
- Delta TT Pro (LimaCorporate, K182099)
- G7 Acetabular System (Biomet, Inc., K140669)

Summary of technology comparison:

The intended use, design, and materials of the Delta Multihole TT Pro Acetabular System are substantially equivalent to the intended use, design, and materials of the predicate devices. Design Control Activities have been completed and the results indicated that the subject device is safe and effective.

Non-clinical testing:

Mechanical testing had demonstrated the device's ability to perform in a substantially equivalent manner to the predicate devices in terms of:

- Push-out, lever-out and torque-out test according to ASTM F1820-13
- Deformation test according to ISO 7206-12:2016
- Unsupported anatomical fatigue deformation

Clinical testing:

Clinical testing was not necessary to demonstrate substantial equivalence of the Delta Multihole TT Pro Acetabular System to the predicate devices.